Am Strande 7
Rostock 18055
Germany
49 381 80113 500
https://www.centogene.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 808
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Andrin Oswald M.D., Ph.D. | Advisor | 479.46k | N/A | 1972 |
Ms. Kim Stratton | CEO & Member of Management Board | N/A | N/A | 1962 |
Mr. Jose Miguel Coego Rios | Chief Financial Officer | N/A | N/A | N/A |
Dr. Patrice P. Denefle Ph.D. | Chief Scientific Officer | N/A | N/A | 1960 |
Dr. Florian Vogel Ph.D. | Chief Process Officer | N/A | N/A | 1982 |
Dr. Peter Bauer M.D. | Chief Medical & Genomic Officer | N/A | N/A | 1969 |
Ms. Bettina Goerner | Chief Data Officer | N/A | N/A | 1984 |
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Centogene N.V.’s ISS governance QualityScore as of 1 January 2023 is 5. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 6; Compensation: 7.